Metronomic Combination Chemotherapy Using Everolimus and Etoposide for the Treatment of non‐Hodgkin Lymphoma

mTOR as a central hub of nutrient signalling and cell growth

Kim, J., & Guan, K. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0205-1 · Cited by 1,067 · see citing works

Etoposide: four decades of development of a topoisomerase II inhibitor

Hande, K. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00228-7 · Cited by 948 · see citing works

Adaptive Therapy

Gatenby, R. A., Silva, A. S., Gillies, R. J., & Frieden, B. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3658 · Cited by 861 · see citing works

mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review

Weichhart, T. (2018) · Gerontology · doi:10.1159/000484629 · Cited by 596 · see citing works

TORC1 inhibition enhances immune function and reduces infections in the elderly

Mannick, J. B., Morris, M., Hockey, H.-U. P., Roma, G., Beibel, M., Kulmatycki, K., Watkins, M., Shavlakadze, T., Zhou, W., Quinn, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1564 · Cited by 496 · see citing works

Metronomics: towards personalized chemotherapy?

André, N., Carré, M., & Pasquier, E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.89 · Cited by 316 · see citing works

Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways

Granato, M., Rizzello, C., Montani, M. S. G., Cuomo, L., Vitillo, M., Santarelli, R., Gonnella, R., D’Orazi, G., Faggioni, A., & Cirone, M. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.12.011 · Cited by 261 · see citing works

Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1

Qian, W., Liu, J., Jin, J., Ni, W., & Xu, W. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.06.021 · Cited by 203 · see citing works

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Kummar, S., Ji, J. J., Morgan, R. J., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D. E., Kiesel, B. F., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 200 · see citing works

Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53

Jing, K., Song, K., Shin, S., Kim, N., Jeong, S., Oh, H.-R., Park, J.-H., Seo, K.-S., Heo, J. Y., Han, J., et al. (2011) · Autophagy · doi:10.4161/auto.7.11.16658 · Cited by 199 · see citing works

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

Barta, S. K., Xue, X., Wang, D., Tamari, R., Lee, J. Y., Mounier, N., Kaplan, L. D., Ribera, J., Spina, M., Tirelli, U., et al. (2013) · Blood · doi:10.1182/blood-2013-04-498964 · Cited by 191 · see citing works

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

Kornblum, N. S., Zhao, F., Manola, J. B., Klein, P., Ramaswamy, B., Brufsky, A., Stella, P. J., Burnette, B. L., Telli, M. L., Makower, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9331 · Cited by 191 · see citing works

Metronomic chemotherapy and immunotherapy in cancer treatment

Chen, Y., Chang, M.-C., & Cheng, W. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.040 · Cited by 162 · see citing works

mTOR: A Cellular Regulator Interface in Health and Disease

Boutouja, F., Stiehm, C. M., & Platta, H. W. (2019) · Cells · doi:10.3390/cells8010018 · Cited by 136 · see citing works

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Witzig, T. E., Reeder, C. B., Han, J., LaPlant, B. R., Stenson, M. J., Tun, H. W., Macon, W. R., Ansell, S. M., Habermann, T. M., Inwards, D. J., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629543 · Cited by 114 · see citing works

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT ‐4 lung subgroup analysis

Fazio, N., Buzzoni, R., Fave, G. D., Tesselaar, M. E. T., Wolin, E. M., Cutsem, E. V., Tomassetti, P., Strosberg, J., Voi, M., Bubuteishvili‐Pacaud, L., et al. (2017) · Cancer Science · doi:10.1111/cas.13427 · Cited by 110 · see citing works

Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage

Filippi‐Chiela, E. C., Silva, M. M. B. E., Thomé, M. P. M., & Lenz, G. (2015) · Autophagy · doi:10.1080/15548627.2015.1009795 · Cited by 98 · see citing works

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

Yao, J. C., Phan, A. T., Jehl, V., Shah, G., & Meric‐Bernstam, F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3923 · Cited by 86 · see citing works

Interaction between mTOR pathway inhibition and autophagy induction attenuates adriamycin-induced vascular smooth muscle cell senescence through decreased expressions of p53/p21/p16

Sung, J. Y., Lee, K. Y., Kim, J., & Choi, H. C. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.08.001 · Cited by 69 · see citing works

Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate

Chen, S.-F., Huang, N.-L., Lin, J., Wu, C.-C., Wang, Y.-R., Yu, Y.-J., Gilson, M. K., & Chan, N. (2018) · Nature Communications · doi:10.1038/s41467-018-05406-y · Cited by 69 · see citing works

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial

Christopoulos, P., Engel-Riedel, W., Grohé, C., Kropf-Sanchen, C., von Pawel, J., Gutz, S., Kollmeier, J., Eberhardt, W., Ukena, D., Baum, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx268 · Cited by 67 · see citing works

ATR/Chk1 signaling induces autophagy through sumoylated RhoB-mediated lysosomal translocation of TSC2 after DNA damage

Liu, M., Zeng, T., Zhang, X., Liu, C., Wu, Z., Yao, L., Xie, C., Xia, H., Lin, Q., Xie, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06556-9 · Cited by 66 · see citing works

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway

Lonetti, A., Cappellini, A., Bertaina, A., Locatelli, F., Pession, A., Buontempo, F., Evangelisti, C., Evangelisti, C., Orsini, E., Zambonin, L., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0344-4 · Cited by 62 · see citing works

Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial

Johnston, P. B., LaPlant, B. R., McPhail, E. D., Habermann, T. M., Inwards, D. J., Micallef, I. N., Colgan, J. P., Nowakowski, G. S., Ansell, S. M., & Witzig, T. E. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30040-0 · Cited by 57 · see citing works

Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer

O’Shaughnessy, J., Beck, J. T., & Royce, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.013 · Cited by 57 · see citing works

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

Shao, Y., Huang, C.-C., Lin, S.-D., Hsu, C., & Cheng, A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2853 · Cited by 45 · see citing works

Targeting nucleolin for better survival in diffuse large B-cell lymphoma

Jain, N. K., Zhu, H., Khashab, T., Ye, Q., George, B., Mathur, R., Singh, R., Berkova, Z., Wise, J. F., Braun, F., et al. (2017) · Leukemia · doi:10.1038/leu.2017.215 · Cited by 43 · see citing works

Autophagy in Premature Senescent Cells Is Activated via AMPK Pathway

Guo, L., Xie, B., & Mao, Z. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13033563 · Cited by 41 · see citing works

Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles

Kwak, G., Jo, S. D., Kim, D., Kim, H., Kim, M. G., Kim, K., Kwon, I. C., & Kim, S. H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.015 · Cited by 39 · see citing works

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas

Bi, C., Zhang, X., Lu, T., Zhang, X., Wang, X., Meng, B., Zhang, H., Wang, P., Vose, J. M., Chan, W. C., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159160 · Cited by 32 · see citing works

Combining low-dose or metronomic chemotherapy with anticancer vaccines

Sow, H. S., & Mattarollo, S. R. (2013) · OncoImmunology · doi:10.4161/onci.27058 · Cited by 31 · see citing works

Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment

Chung, S. W., Kim, G. C., Kweon, S., Lee, H., Choi, J. U., Mahmud, F., Chang, H. W., Kim, J. W., Son, W., Kim, S. Y., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.007 · Cited by 27 · see citing works

Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders

Pierdominici, M., Barbati, C., Vomero, M., Locatelli, S. L., Carlo‐Stella, C., Ortona, E., & Malorni, W. (2013) · The FASEB Journal · doi:10.1096/fj.13-235655 · Cited by 24 · see citing works

Role of Nitric Oxide in the Chemistry and Anticancer Activity of Etoposide (VP-16,213)

Sinha, B. K., Bhattacharjee, S., Chatterjee, S., Jiang, J., Motten, A. G., Kumar, A., Espey, M. G., & Mason, R. P. (2013) · Chemical Research in Toxicology · doi:10.1021/tx300480q · Cited by 23 · see citing works

Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma

Chiang, C.-T., Yeh, P.-Y., Gao, M., Chen, C.-W. D., Yeh, L.-C., Feng, W.-C., Kuo, S., Hsu, C., Lu, Y., & Cheng, A. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.07.005 · Cited by 23 · see citing works

The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma

Zeng, J., Yang, L., Huang, F., Hong, T., Zhihui, H., Lei, J., Sun, H., Lu, Y., & Hao, X. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3136-1 · Cited by 18 · see citing works

mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL

Vo, T.-T. T., Lee, J. S., Nguyen, D. M., Lui, B., Pandori, W., Khaw, A., Mallya, S., Lu, M., Müschen, M., Konopleva, M. Y., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0024 · Cited by 15 · see citing works

Therapy-activated stromal cells can dictate tumor fate

Kerbel, R. S., & Shaked, Y. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20161845 · Cited by 10 · see citing works

Metronomic chemotherapy for elderly and/or frail patients

Romero, D. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.33 · Cited by 10 · see citing works

Hypoxia Signaling in Cancer: From Basics to Clinical Practice

Sebestyén, A., Kopper, L., Dankó, T., & Tímár, J. (2021) · Pathology and Oncology Research · doi:10.3389/pore.2021.1609802 · Cited by 110 · see citing works

Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach

Kashkooli, F. M., & Soltani, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-00989-x · Cited by 44 · see citing works

Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies

Fakhri, S., Moradi, S. Z., DeLiberto, L. K., & Bishayee, A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114989 · Cited by 38 · see citing works

Metronomic chemotherapy in cancer treatment: new wine in an old bottle

Wu, H., Zhou, H.-X., Chen, L., & Wang, S.-S. (2024) · Theranostics · doi:10.7150/thno.95619 · Cited by 20 · see citing works

S100A8 promotes chemoresistance via augmenting autophagy in B‑cell lymphoma cells

Zhang, L., Zhou, S., Zhou, T., Yuan, K., Li, X., & Tang, J. (2020) · Oncology Reports · doi:10.3892/or.2020.7841 · Cited by 14 · see citing works

Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds

Cox, M. C., & Bocci, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.018 · Cited by 13 · see citing works

Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules

Banchi, M., Cox, M. C., & Bocci, G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216900 · Cited by 10 · see citing works

All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma

Cox, M. C., Banchi, M., Pelliccia, S., Napoli, A. D., Marcheselli, L., Patti, C., Borza, P. A., Battistini, R., Gregorio, F. D., Orlandi, P., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04172-3 · Cited by 10 · see citing works

Medication Safety in Intravenous Therapy: Compatibility of Etoposide with Frequently Drugs Used in Tumour Critical Care During Simulated Y-Site Administration

Ding, H., Tong, T., Liu, S., Tang, L., & Chen, Z. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s489534 · Cited by 1 · see citing works

Chimiothérapie métronomique : stratégie thérapeutique prometteuse de prise en charge de l'hétérogénéité intratumorale par action sur le métabolisme énergétique pour contrôler la résistance aux traitements anti-cancéreux

Bondarenko, M. (2021) · doi:10.70675/b6c8631azd6aaz42e9z9cf3z65208b9697a3

The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma

Zeng, J., Yang, L., Huang, F., Hong, T., Zhihui, H., Lei, J., Sun, H., Lu, Y., & Hao, X. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3136-1 · Cited by 18 · see citing works

Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds

Cox, M. C., & Bocci, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.018 · Cited by 13 · see citing works

PP-041 CD5(–) MANTLE CELL LYMPHOMA: A CASE REPORT

Ak, M. A., Toka, B., Ergen, S., Tekin, İ. Ö., & Ertop, I. (2014) · Leukemia Research · doi:10.1016/s0145-2126(14)70095-5

Efficacy of metronomic chemotherapy with oral cyclophosphamide and methotrexate in patients with non-Hodgkin lymphoma: A retrospective analysis

Jung, J. Y., Jang, G.-E., Song, H., Kim, H. S., Choi, D. R., Kwon, J. H., Kim, H. Y., Han, B., Kim, J. H., Kim, H. J., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32941-0 · Cited by 1 · see citing works

[Mitoxantrone-containing combination chemotherapy in patients with non-Hodgkin's lymphoma].

Kimura, I., Ohnoshi, T., Masaoka, T., Sampi, K., & Namba, K. (1986) · PubMed · Cited by 2 · see citing works